Year: 2024

A Landmark Year of Growth, New Leadership, and Strategic Advancements for Ladybug Nutratech TULSA, Okla., Dec. 16, 2024 (GLOBE NEWSWIRE) — Ladybug Resource Group, Inc. (“Ladybug”) (OTC PINK: LBRG), operating as Ladybug Nutratech, proudly announces a remarkable milestone in its history, surpassing $9.6 million USD in revenue for the nine months ending September 30, 2024. This achievement represents a significant increase of approximately $7.5 million compared to total revenues generated in 2023. This monumental growth underscores Ladybug’s steadfast commitment to innovation, strategic market positioning, and sustainable value creation for shareholders. “This year has been a defining moment for our company,” stated a member of the Board of Directors. “We are delivering on our promise to expand market...

– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) – SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration with Celest Therapeutics (Shanghai) Co. Ltd (“Celest”). SN301A utilizes the anti-GPC3 + crIL-15 (each as defined below) SENTI-301A Gene Circuit developed by Senti Bio and refers to the chimeric antigen receptor natural killer (“CAR-NK”) product candidate manufactured by Celest...

Core Analysis Highlights Key Geological Features Supporting Hydrogen Storage Potential at Robinsons River Salt Project VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company”) is pleased to announce the completion of core logging and preliminary analysis of samples from Well VW231, part of the Robinsons River Salt Project (“The Project”) in Newfoundland. This study was conducted in collaboration with Dr. Hassan Dehghanpour and his research team at the University of Alberta under an NSERC Alliance research partnership, the findings highlight the geological suitability of the site for underground hydrogen storage (UHS). The primary objective of the study was to evaluate the feasibility and safety of using the salt dome within the Robinsons River...

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and transformative genetic medicines Proprietary intravitreal vector R100 demonstrated superior transduction and transgene expression compared to AAV2, the standard AAV serotypes used in retinal gene therapies, in all three human retinal cell types evaluated in vitro (up to ~10-fold improvement), and in all primate retinal cell layers after intravitreal injection in vivo Intravitreal administration of the R100 vector-based 4D-150 genetic medicine in nonhuman primate wet AMD model was well tolerated, led to robust retinal expression of dual transgenes (aflibercept and anti-VEGF C) and complete suppression of severe CNV choroidal neovascularization lesions 4D-150...

ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trials Roflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile for up to 56 weeks of treatment Approximately 1.8 million children with atopic dermatitis (AD) aged 2 to 5 are topically treated in the United StatesWESTLAKE VILLAGE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for ZORYVE (roflumilast) cream 0.05%, a once-daily, next generation phosphodiesterase 4 (PDE4) inhibitor, for the topical treatment of mild to moderate...

Austin, Dec. 16, 2024 (GLOBE NEWSWIRE) — TurboCheck, the #1 tool for digital identity verification and authID® (Nasdaq: AUID), a leading provider of biometric identity verification and authentication solutions, have announced a groundbreaking partnership to tackle the escalating challenges of hiring fraud in the digital age. To date, TurboCheck has identified over 200,000 fake candidates, demonstrating the scale of the problem and the critical need for advanced fraud detection solutions. This collaboration combines TurboCheck’s advanced fraud detection platform with authID’s state-of-the-art biometric technology, providing employers and staffing firms with unparalleled confidence in candidate authenticity. Addressing the Growing Threat of Hiring Fraud The surge in artificial intelligence (AI) and online tools has revolutionized...

NESS ZIONA, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received written notification from the NYSE American LLC (“NYSE American”), dated December 10, 2024, stating that the Company has regained compliance with all NYSE American LLC continued listing standards. Specifically, the Company has resolved prior listing deficiencies raised on May 23, 2024, by NYSE American and set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the “Company Guide”). NYSE American confirmed that the Company has demonstrated compliance with the continued listing standard for a period of two consecutive quarters pursuant...

SHEFFIELD, United Kingdom, Dec. 16, 2024 (GLOBE NEWSWIRE) — Caro Holdings Inc. (OTC: CAHO) has partnered with Drunken Horse Gin to provide e-commerce support and targeted digital marketing campaigns for seasonal sales, including Black Friday, Christmas, and Valentine’s Day. This collaboration is designed to help Drunken Horse Gin navigate peak sales periods by enhancing its online presence and improving visibility. Drunken Horse Gin, known for its award-winning super-premium gin, is expanding its seasonal offerings tailored to the premium market. Seasonal sales are key opportunities for brands to engage with consumers, and digital strategies like social selling play a critical role in success. With many shoppers starting their holiday purchasing as early as October, well-executed campaigns are essential for boosting visibility...

John W. Casella with Courtney HierJohn W. Casella, Chairman & CEO of Casella Waste Systems, Inc. hugs Courtney Hier, daughter of Ken Hier Sr. at the dedication of the Kenneth A. Hier Sr. CDL Training Center.Crowd of OnlookersA full crowd of people at Casella’s dedication of the Kenneth A. Hier CDL Training CenterCourtney Hier Podium ShotCourtney Hier, daughter of Ken Hier Sr. provides remarks at the dedication of the Kenneth A. Hier Sr. CDL Training CenterJohn W. Casella Podium ShotJohn W. Casella, Chairman & CEO of Casella Waste Systems, Inc., provides remarks at the dedication of the Kenneth A. Hier Sr. CDL Training Center.Michael E. Hoffman Podium ShotMichael E. Hoffman, President & CEO of the National Waste and Recycling Association, provides remarks at the dedication...

BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (“LeMaitre”) (Nasdaq: LMAT) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). LeMaitre also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22,500,000 aggregate principal amount of notes. The notes will be senior, unsecured obligations of LeMaitre, will accrue interest payable semi-annually in arrears, and will mature on February 1, 2030,...